Challenger exits as substantial Telix Pharmaceuticals shareholder

Challenger Limited, alongside its listed associated entities, announced it ceased to be a substantial holder in Telix Pharmaceuticals Ltd as of August 28, 2025. The previous notice of substantial holding was given on August 25, 2025.

The change in relevant interest was primarily driven by a significant "Sell - Transfer" transaction on August 21, 2025, involving AUD 6,306,203 and reducing securities by 348,409. This was partially offset by "Buy" transactions on August 22, 2025, totaling AUD 4,553,387 and increasing securities by 248,014. From August 28, 2025, a series of "Sell" transactions further reduced the total number of securities held, with the aggregate change in securities for this period resulting in a reduction of 585,347.

Linda Matthews, company secretary of Challenger Limited, signed the notice on September 1, 2025.